Targacept net operating revenues rise marginally in Q3
Targacept has posted a net income of $2.49m for the third quarter 2010, or $0.08 per diluted share, compared to $1.33m, or $0.05 per diluted share, for the
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.